A randomised, placebo-controlled, double-blinded, cross-over, Phase 1 study evaluating the safety and preliminary efficacy of the GLP 1 analogue ROSE-010 on appetite and food intake in overweight and obese subjects.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507758-34-00

Acronym

RP-23-01

Enrollment

Registered

2023-11-09

Start date

2023-11-10

Completion date

2024-01-16

Last updated

2023-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Overweight

None listed

Sex/Gender

All

Age

18 Years to No maximum

Sweden

None listed

Source: EU CTIS · Data processed: Feb 4, 2026